Synthesis and antitumor activity of conjugates of muramyldipeptide or normuramyldipeptide with hydroxyacridine/acridone derivatives

Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2003, Pages 183-189

  Dzierzbicka, Krystyna ^a   Kołodziejczyk, Aleksander M ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; ACRIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOXYL GROUP; ESTER; ESTER DERIVATIVE; GLUTAMINE DERIVATIVE; HYDROXYACRIDINE; HYDROXYL GROUP; MURAMYL DIPEPTIDE; MURAMYL DIPEPTIDE DERIVATIVE; NORMURAMYL DIPEPTIDE; O [(1 O BENZYL N ACETYLMURAMYLALANYL DEXTRO GAMMA ISOGLUTAMINYL) N 2 ETHYL]ACRIDINE 4 CARBOXAMIDE; O [(1 O BENZYL N ACETYLMURAMYLALANYL DEXTRO GAMMA ISOGLUTAMINYL) N 3 PROPYL]ACRIDINE 4 CARBOXAMIDE ESTER; O [(1 O BENZYL N ACETYLMURAMYLALANYL DEXTRO GAMMA ISOGLUTAMINYL) N 4 BUTYL]ACRIDINE 4 CARBOXAMIDE ESTER; O [(1 O BENZYL N ACETYLMURAMYLVALYL DEXTRO GAMMA ISOGLUTAMINYL) N 2 ETHYL] 9 ACRIDONE 4 CARBOXAMIDE ESTER; O [(1 O BENZYL N ACETYLMURAMYLVALYL DEXTRO GAMMA ISOGLUTAMINYL) N 3 PROPYL]ACRIDINE 4 CARBOXAMIDE ESTER; O [(1 O BENZYL N ACETYLNORMURAMYLALANYL DEXTRO GAMMA ISOGLUTAMINYL) N 2 ETHYL] 9 ACRIDONE 4 CARBOXAMIDE ESTER; O [(1 O BENZYL N ACETYLNORMURAMYLALANYL DEXTRO GAMMA ISOGLUTAMINYL) N 2 ETHYL]ACRIDINE 4 CARBOXAMIDE ESTER; O [(1 O BENZYL N ACETYLNORMURAMYLALANYL DEXTRO GAMMA ISOGLUTAMINYL) N 3 PROPYL] 9 ACRIDONE 4 CARBOXAMIDE ESTER; O [(1 O BENZYL N ACETYLNORMURAMYLVALYL DEXTRO GAMMA ISOGLUTAMINYL) N 3 PROPYL] 9 ACRIDONE 4 CARBOXAMIDE ESTER; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LINE; CHEMICAL BOND; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MELANOMA; MOUSE; NONHUMAN; PROSTATE CARCINOMA; TUMOR XENOGRAFT;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037413547     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020991m     Document Type: Article

References (33)

1. Dzierzbicka, K.; Kołodziejczyk, A. M.; Wysocka-Skrzela, B.; Myśliwski, A.; Sosnowska, D. Synthesis and antitumor activity of conjugates of muramyldipeptides, normuramyldipeptide, and desmuramyldipeptides with acridine/acridone derivatives. J. Med. Chem. 2001, 44, 3606-3614.
2. Baschang, G. Muramylpeptides and lipopeptides: Studies towards immunostimulants. Tetrahedron 1989, 45, 6331-6360.
3. Sosnowska, D.; Dzierzbicka, K.; Myśliwski A.; Kołodziejczyk, A. M. Muroctasin, a muramyl dipeptide derivative. Postepy Hig. Med. Dośw. 1992, 46, 73-82.
4. Dzierzbicka, K.; Gozdowska, M.; Kołodziejczyk, A. M. L-MTPPE - A potential drug for cancer therapy. Postepy Hig. Med. Dośw. 1997, 51 (2), 227-236.
5. Kołodziejczyk, A. M.; Dzierzbicka, K.; Kołodziejczyk, A. S. A new class of anticancer agents: Conjugates of MDP and acridine/acridone derivatives. Polish J. Chem. 1994, 68, 1023-1029.
6. Gozdowska, M.; Dzierzbicka, K.; Wysocka-Skrzela, B.; Kołodziejczyk, A. M. Synthesis and in vitro anticancer activity of conjugates of MDP with amino-acridine/acridone derivatives. Polish J. Chem. 1997, 71, 767-773.
7. Dzierzbicka, K.; Gozdowska, M.; Wysocka-Skrzela, B.; Kołodziejczyk, A. M. Synthesis and anticancer activites of new MDP conjugates with amino-acridine/acridone derivatives. Acta Pol. Pharm. Drug Res. 1999, 56, 20-24.
8. Dzierzbicka, K.; Kołodziejczyk, A. M.; Wysocka-Skrzela, B.; Kołodziejczyk, A. S. Synthesis of muramyl dipeptide conjugated with acridine derivatives, showing anti-HIV-1 and anticancer activity. Pol. J. Chem. 1994, 68, 37-45.
9. Atwell, G. J.; Rewcastle, G. W.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem. 1987, 30, 664-669.
10. Finlay, G. J.; Riou, J. F.; Baguley, B. C. From amsacrine to DACA (N-[2-(dimethylamino) ethyl]acridine-4-carboxamide): Selectivity for topoisomerases I and II among acridine derivatives. Eur. J. Cancer 1996, 32A, 708-714.
11. Baguley, B. C.; Zhuang, L.; Marshall, E, Experimental solid tumor activity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother. Pharmacol. 1995, 36, 244-248.
12. Schneider, E.; Darkin, S. J.; Lawson, P. A.; Ching, L. M.; Ralph, R. K.; Baguley, B. C. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino) ethyl]-acridine-4-carboxamide: Role of DNA topoisomerase II. Eur. J. Cancer and Clin. Oncol. 1988, 24, 1783-1790.
13. Finlay, G. J.; Marshall, E. S.; Matthews, J. H. L.; Paull, K. D.; Baguley, B. C. In vitro assessment of N-[2-(dimethylamino)ethyl](dimethylamino)ethyl]-acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother. Pharmacol. 1993, 31, 401-406.
14. Davey, R. A.; Su, G. M.; Hargrave, R. M.; Harvie, R. M.; Baguley, B. C.; Davey, M. W. The potential of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemother. Pharmacol. 1997, 39, 424.
15. de Bono, J. S.; Propper, D.; Ellard, S.; Steiner, J.; Bevan, P.; Dobbs, N.; Flannigan, E.; Ganesan, T. S.; Talbot, D. C.; Campbell, S.; Twelves, C.; Harris, A. A phase I study of XR5000 (DACA) by 120 h intravenous infusion. In Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy; 1998; p 449.
16. Haldane, A.; Finlay, G. J.; Hay, M. P.; Denny, W. A.; Baguley, B. C. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Anti-Cancer Drug Design 1999, 14, 275-280.
17. Wysocka-Skrzela, B.; Ledóchowski, A.; Radzikowski, C. 1-Nitro-9-hydroxyalkylamino-acridines or their salts. European Patent Application, 0038572, 1981; Chem. Abstr. 1982, 96, 68847u.
18. Chen, Y.; Badithe, A. T.; Garikapaty, V. P. S.; Liu, X.; Szostek, A.; Wysocka-Skrzela, B.; Banerjee, D.; Konopa, J.; Miller, D. G.; Tiwari, K. R. Pre-clinical studies of 1-nitroacridine derivatives: Effective antitumor agents for prostate cancer. Proc. Am. Assoc. Cancer Res. 2002, 43, 77.
19. Lefrancier, P.; Choay, J.; Derrieu, M.; Lederman, I. Synthesis of N-acetylmuramyl-L-alanyl-D-isoglutamine, an adjuvant of the immune response and some N-acetylmuramyl peptide analogues. Int. J. Pept. Protein Res. 1977, 9, 249-257.
20. Gozdowska, M. Ph.D. Thesis, Gdansk University of Technology, 1998.
21. Dzierzbicka, K.; Kołodziejczyk, A. M. A convenient synthesis of isoglutamine and glutamine derivatives. Pol. J. Chem. 1991, 65, 1437-1439.
22. Rewcastle, G. W.; Atwell, G. J.; Chambers, D.; Baguley, C.; Denny, W. A. Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem. 1986, 29, 471-477.
23. Atwell, G. J.; Cain, B. F.; Baguley, B. C.; Finlay, G. J.; Denny, W. A. Potential antitumor agents. Part 43. Synthesis and biological activity of dibasic 4-carboxamido-9-amino-acridines, a new class of antitumor agent. J. Med. Chem. 1984, 27, 1481-1485.
24. Lee, H. H.; Palmer, B. D.; Baguley, B. C.; Chin, M.; McFadyen, W. D.; Wickham, G.; Thorsbourne-Palmer, D.; Wakelin, L. P. G.; Denny, W. A. DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum (II). J. Med. Chem. 1992, 35, 2983-2987.
25. Pawlak, J. W.; Pawlak, K.; Konopa, J. Cytotoxic and antitumor activity of 1-nitroacridines as an aftereffect of their interstrand DNA cross-linking. Cancer Res. 1984, 44, 4289-4296.
26. Gorlewska, K.; Mazerska, Z.; Sowiński, P.; Konopa, J. Products of metabolic activation of the antitumor drug Ledakrin (Nitracrine) in vitro. Chem. Res. Toxicol. 2001, 14 (1), 1-10.
27. Wilson, W. R.; Denny, W. A.; Twigden, S.; Baguley, B. C.; Probert, J. C. Selective toxicity of nitracrine to hypoxic mammalian cells. Br. J. Cancer 1984, 49, 215-223.
28. Wilson, W. R.; Denny, W. A.; Steward, G. M.; Fenn, A.; Probert, J. C. Reductive metabolism and hypoxia-selective metabolism of nitracrine. Int. J. Radiat. Oncol. Biol. Phys. 1986, 12, 1235-1238.
29. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
30. Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: Cancer drug discovery and development program. Semin. Oncol. 1992, 19, 622-638.
31. Kruszewski, A. A.; Dzierzbicka, K.; Urbanowska, E.; Kot, M.; Jȩdrzejczak, W. W.; Kołodziejczyk, A. The effects of intraperitoneal administration of MDP-C867 on cell kinetics and transplantable tumour growth in peritoneal cavity, preliminary results. Presented at the 2nd Israel-Poland Symposium on the Chemistry and Biology of Peptides and Proteins, Jerusalem, 1995, s.41.
32. Personal communication from NCI, Bethesda, MD.
33. Plowman, J.; Dykes, D. J.; Hollingshead, M.; Simpson-Herren, L.; Alley, M. C. Human tumor xenograft models in NCI drug development. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval; Teicher, B., Ed.; Humana Press: Totowa, NJ, 1997; pp 101-125.